BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011;51:170-82. [PMID: 22139852 DOI: 10.1007/s12026-011-8262-6] [Cited by in Crossref: 156] [Cited by in F6Publishing: 141] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Tevis KM, Cecchi RJ, Colson YL, Grinstaff MW. Mimicking the tumor microenvironment to regulate macrophage phenotype and assessing chemotherapeutic efficacy in embedded cancer cell/macrophage spheroid models. Acta Biomater 2017;50:271-9. [PMID: 28011141 DOI: 10.1016/j.actbio.2016.12.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
2 Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013;2:e23562. [PMID: 23687622 DOI: 10.4161/onci.23562] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 13.7] [Reference Citation Analysis]
3 Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta. 2013;1835:170-179. [PMID: 23287570 DOI: 10.1016/j.bbcan.2012.12.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 83] [Article Influence: 5.3] [Reference Citation Analysis]
4 Zeng S, Chen Y, Chen Y, Liu H. Lipid–polymer hybrid nanoparticles for synergistic drug delivery to overcome cancer drug resistance. New J Chem 2017;41:1518-25. [DOI: 10.1039/c6nj02819e] [Cited by in Crossref: 11] [Article Influence: 2.8] [Reference Citation Analysis]
5 Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, Sundararajan S. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel) 2019;8:E51. [PMID: 31640266 DOI: 10.3390/antib8040051] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
6 Baxevanis CN, Papamichail M, Perez SA. Immune classification of colorectal cancer patients: impressive but how complete? Expert Opin Biol Ther. 2013;13:517-526. [PMID: 23289642 DOI: 10.1517/14712598.2013.751971] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
7 Walter SG, Scheidt S, Nißler R, Gaisendrees C, Zarghooni K, Schildberg FA. In-Depth Characterization of Stromal Cells within the Tumor Microenvironment Yields Novel Therapeutic Targets. Cancers (Basel) 2021;13:1466. [PMID: 33806802 DOI: 10.3390/cancers13061466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pasqual-Melo G, Sagwal SK, Freund E, Gandhirajan RK, Frey B, von Woedtke T, Gaipl U, Bekeschus S. Combination of Gas Plasma and Radiotherapy Has Immunostimulatory Potential and Additive Toxicity in Murine Melanoma Cells in Vitro. Int J Mol Sci 2020;21:E1379. [PMID: 32085661 DOI: 10.3390/ijms21041379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
9 Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, Vendemiale G, Serviddio G. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One 2016;11:e0167934. [PMID: 27997563 DOI: 10.1371/journal.pone.0167934] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
10 Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-Associated Macrophages: Recent Insights and Therapies. Front Oncol 2020;10:188. [PMID: 32161718 DOI: 10.3389/fonc.2020.00188] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 88.0] [Reference Citation Analysis]
11 Cevey ÁC, Penas FN, Alba Soto CD, Mirkin GA, Goren NB. IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole. Front Immunol 2019;10:1267. [PMID: 31214200 DOI: 10.3389/fimmu.2019.01267] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
12 Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC, Liu Z, Jones J, D'Apuzzo M, Pal S, Kortylewski M. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol 2017;102:423-36. [PMID: 28533357 DOI: 10.1189/jlb.3MA1016-451RR] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
13 Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012;1:458-66. [PMID: 22754764 DOI: 10.4161/onci.19855] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 105.0] [Reference Citation Analysis]
14 Sun L, Lin Z, Duan X, Qi H, Yang N, Li M, Xing E, Sun Y, Yu M, Li W, Lu J. Suppression of the Production of Transforming Growth Factor β1, Interleukin-10, and Vascular Endothelial Growth Factor in the B16F10 Cells by Ganoderma lucidum Polysaccharides. Journal of Interferon & Cytokine Research 2014;34:667-75. [DOI: 10.1089/jir.2012.0101] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
15 Wu JJ, Yang Y, Peng WT, Sun JC, Sun WY, Wei W. G protein-coupled receptor kinase 2 regulating β2-adrenergic receptor signaling in M2-polarized macrophages contributes to hepatocellular carcinoma progression. Onco Targets Ther 2019;12:5499-513. [PMID: 31371988 DOI: 10.2147/OTT.S209291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rybojad P, Jabłonka A, Wilczyńska B, Tabarkiewicz J. Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer. Eur J Surg Oncol 2013;39:1269-77. [PMID: 23906695 DOI: 10.1016/j.ejso.2013.07.083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
17 Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, Ding JL. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest. 2013;93:844-854. [PMID: 23752129 DOI: 10.1038/labinvest.2013.69] [Cited by in Crossref: 244] [Cited by in F6Publishing: 247] [Article Influence: 30.5] [Reference Citation Analysis]
18 Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J, Petrova PS, Uger RA, Viller NN. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS One 2017;12:e0187262. [PMID: 29084248 DOI: 10.1371/journal.pone.0187262] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
19 Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol 2014;96:1109-18. [PMID: 25170116 DOI: 10.1189/jlb.3A0414-210R] [Cited by in Crossref: 95] [Cited by in F6Publishing: 67] [Article Influence: 13.6] [Reference Citation Analysis]
20 Xie X, O'Neill W, Pan Q. Immunotherapy for head and neck cancer: the future of treatment? Expert Opin Biol Ther 2017;17:701-8. [PMID: 28368668 DOI: 10.1080/14712598.2017.1315100] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
21 Mola S, Pinton G, Erreni M, Corazzari M, De Andrea M, Grolla AA, Martini V, Moro L, Porta C. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. Int J Mol Sci 2021;22:4391. [PMID: 33922336 DOI: 10.3390/ijms22094391] [Reference Citation Analysis]
22 Zhong X, Zhou Y, Cao Y, Ding J, Wang P, Luo Y, Liu H, Zhu Z, Jing X. Enhanced antitumor efficacy through microwave ablation combined with a dendritic cell-derived exosome vaccine in hepatocellular carcinoma. Int J Hyperthermia 2020;37:1210-8. [PMID: 33100037 DOI: 10.1080/02656736.2020.1836406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Naiyer MM, Saha S, Hemke V, Roy S, Singh S, Musti KV, Saha B. Identification and characterization of a human IL-10 receptor antagonist. Hum Immunol 2013;74:28-31. [PMID: 23000375 DOI: 10.1016/j.humimm.2012.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
24 Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res 2012;31:47. [PMID: 22592077 DOI: 10.1186/1756-9966-31-47] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
25 Dudek I, Skoda M, Jarosz A, Szukiewicz D. The Molecular Influence of Graphene and Graphene Oxide on the Immune System Under In Vitro and In Vivo Conditions. Arch Immunol Ther Exp (Warsz) 2016;64:195-215. [PMID: 26502273 DOI: 10.1007/s00005-015-0369-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
26 Tecchio C, Scapini P, Pizzolo G, Cassatella MA. On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol. 2013;23:159-170. [PMID: 23410636 DOI: 10.1016/j.semcancer.2013.02.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 12.4] [Reference Citation Analysis]
27 Devarasetty M, Forsythe SD, Shelkey E, Soker S. In Vitro Modeling of the Tumor Microenvironment in Tumor Organoids. Tissue Eng Regen Med 2020;17:759-71. [PMID: 32399776 DOI: 10.1007/s13770-020-00258-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
28 Banday MZ, Sameer AS, Chowdri NA, Haq E. Interleukin-10 −592C/A, but not −1082A/G promoter single nucleotide polymorphism, is associated with a decreased risk of colorectal cancer in an ethnic Kashmiri population: a case–control study. European Journal of Cancer Prevention 2017;26:476-90. [DOI: 10.1097/cej.0000000000000370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Matsui M, Kajikuri J, Kito H, Endo K, Hasegawa Y, Murate S, Ohya S. Inhibition of Interleukin 10 Transcription through the SMAD2/3 Signaling Pathway by Ca 2+ -Activated K + Channel K Ca 3.1 Activation in Human T-Cell Lymphoma HuT-78 Cells. Mol Pharmacol 2019;95:294-302. [DOI: 10.1124/mol.118.114405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
30 Ni G, Wang Y, Wu X, Wang X, Chen S, Liu X. Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. Immunology Letters 2012;148:126-32. [DOI: 10.1016/j.imlet.2012.10.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
31 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wu Y, Liu Y, Dong Y, Vadgama J. Diabetes-associated dysregulated cytokines and cancer. Integr Cancer Sci Ther 2016;3:370-8. [PMID: 29930868 DOI: 10.15761/ICST.1000173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology 2016;28:64-72. [DOI: 10.1016/j.smim.2015.11.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
34 Koronellos N, Yapijakis C, Katoulis A, Avgoustidis D, Vylliotis A, Papakosta V, Diamantopoulou S, Zografos O, Vairaktari G, Vairaktaris E, Vassiliou S. Association study indicates combined effect of interleukin-10 and angiotensin-converting enzyme in basal cell carcinoma development. Arch Dermatol Res 2021;313:373-80. [PMID: 32772162 DOI: 10.1007/s00403-020-02113-x] [Reference Citation Analysis]
35 Li Z, Liu X, Guo R, Wang P. CD4+Foxp3- type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages. Int J Biochem Cell Biol 2016;81:1-9. [PMID: 27644153 DOI: 10.1016/j.biocel.2016.09.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
36 Xu X, Liu X, Long J, Hu Z, Zheng Q, Zhang C, Li L, Wang Y, Jia Y, Qiu W, Zhou J, Yao W, Zeng Z. Interleukin-10 reorganizes the cytoskeleton of mature dendritic cells leading to their impaired biophysical properties and motilities. PLoS One 2017;12:e0172523. [PMID: 28234961 DOI: 10.1371/journal.pone.0172523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Li L, Ma Y, Liu S, Zhang J, Xu X. Interleukin 10 promotes immune response by increasing the survival of activated CD8+ T cells in human papillomavirus 16-infected cervical cancer. Tumor Biol 2016;37:16093-101. [DOI: 10.1007/s13277-016-5466-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
38 Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin Cytom 2020;98:299-327. [PMID: 32352629 DOI: 10.1002/cyto.b.21880] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
39 Prado-garcia H, Romero-garcia S, Lopez-gonzalez JS. The Role of Exhaustion in Tumor-Induced T Cell Dysfunction in Cancer. In: Rezaei N, editor. Cancer Immunology. Berlin: Springer Berlin Heidelberg; 2015. pp. 61-75. [DOI: 10.1007/978-3-662-44006-3_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Sendra Gisbert L, Miguel Matas A, Sabater Ortí L, Herrero MJ, Sabater Olivas L, Montalvá Orón EM, Frasson M, Abargues López R, López-Andújar R, García-Granero Ximénez E, Aliño Pellicer SF. Efficacy of hydrodynamic interleukin 10 gene transfer in human liver segments with interest in transplantation. Liver Transpl 2017;23:50-62. [PMID: 27783460 DOI: 10.1002/lt.24667] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Fernandes JV, Cobucci RN, Jatobá CA, Fernandes TA, de Azevedo JW, de Araújo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21:527-534. [PMID: 25740073 DOI: 10.1007/s12253-015-9913-z] [Cited by in Crossref: 106] [Cited by in F6Publishing: 97] [Article Influence: 17.7] [Reference Citation Analysis]
42 Iwamoto C, Ohuchida K, Shinkawa T, Okuda S, Otsubo Y, Okumura T, Sagara A, Koikawa K, Ando Y, Shindo K, Ikenaga N, Nakata K, Moriyama T, Miyasaka Y, Ohtsuka T, Eto M, Akashi K, Nakamura M. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Cancer Lett 2021;512:15-27. [PMID: 33961925 DOI: 10.1016/j.canlet.2021.04.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Fyrstenberg Laursen M, Kofod-Olsen E, Agger R. Activation of dendritic cells by targeted DNA: a potential addition to the armamentarium for anti-cancer immunotherapy. Cancer Immunol Immunother 2019;68:1875-80. [PMID: 31559451 DOI: 10.1007/s00262-019-02400-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. J Clin Immunol. 2017;37:638-643. [PMID: 28871523 DOI: 10.1007/s10875-017-0439-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
45 Atretkhany KN, Drutskaya MS, Nedospasov SA, Grivennikov SI, Kuprash DV. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther 2016;168:98-112. [PMID: 27613100 DOI: 10.1016/j.pharmthera.2016.09.011] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
46 Rossowska J, Anger N, Kicielińska J, Pajtasz-Piasecka E, Bielawska-Pohl A, Wojas-Turek J, Duś D. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response. Immunobiology 2015;220:389-98. [PMID: 25454807 DOI: 10.1016/j.imbio.2014.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
47 Roesch S, Rapp C, Dettling S, Herold-Mende C. When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma. Int J Mol Sci 2018;19:E436. [PMID: 29389898 DOI: 10.3390/ijms19020436] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 36.7] [Reference Citation Analysis]
48 Andersen RS, Anand A, Harwood DSL, Kristensen BW. Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy. Cancers (Basel) 2021;13:4255. [PMID: 34503065 DOI: 10.3390/cancers13174255] [Reference Citation Analysis]
49 Mencarelli A, Graziosi L, Renga B, Cipriani S, D'Amore C, Francisci D, Bruno A, Baldelli F, Donini A, Fiorucci S. CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Transl Oncol 2013;6:784-93. [PMID: 24466382 DOI: 10.1593/tlo.13499] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
50 Nasser H, St John MA. The promise of immunotherapy in the treatment of young adults with oral tongue cancer. Laryngoscope Investig Otolaryngol 2020;5:235-42. [PMID: 32337355 DOI: 10.1002/lio2.366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK. Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy 2015;7:499-512. [DOI: 10.2217/imt.15.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
52 Chuang MH, Chang JT, Hsu LJ, Jan MS, Lu FJ. Antitumor Activity of the Chinese Medicine JC-001 Is Mediated by Immunomodulation in a Murine Model of Hepatocellular Carcinoma. Integr Cancer Ther 2017;16:516-25. [PMID: 27698264 DOI: 10.1177/1534735416664173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
53 Long A, Dominguez D, Qin L, Chen S, Fan J, Zhang M, Fang D, Zhang Y, Kuzel TM, Zhang B. Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression. J Immunol 2018;201:3456-64. [PMID: 30373846 DOI: 10.4049/jimmunol.1800173] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
54 Traba J, Sack MN, Waldmann TA, Anton OM. Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance. Front Immunol 2021;12:657293. [PMID: 34079545 DOI: 10.3389/fimmu.2021.657293] [Reference Citation Analysis]
55 Krejsgaard T, Willerslev-Olsen A, Lindahl LM, Bonefeld CM, Koralov SB, Geisler C, Wasik MA, Gniadecki R, Kilian M, Iversen L, Woetmann A, Odum N. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 2014;124:761-70. [PMID: 24957145 DOI: 10.1182/blood-2014-01-551184] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
56 Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. Front Immunol 2018;9:444. [PMID: 29593717 DOI: 10.3389/fimmu.2018.00444] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
57 Härdle L, Bachmann M, Bollmann F, Pautz A, Schmid T, Eberhardt W, Kleinert H, Pfeilschifter J, Mühl H. Tristetraprolin regulation of interleukin-22 production. Sci Rep 2015;5:15112. [PMID: 26486958 DOI: 10.1038/srep15112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
58 Costa Brandão Berti F, Brajão de Oliveira K; 1 Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Londrina State University, Londrina, Parana, Brazil, 2 Departamento de Ciências Patológicas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Campus Universitário, CEP 86051-970, Londrina, Paraná, Brazil. . AIMS Allergy and Immunology 2018;2:88-97. [DOI: 10.3934/allergy.2018.2.88] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Schmiechen ZC, Stromnes IM. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Front Immunol 2020;11:613815. [PMID: 33584701 DOI: 10.3389/fimmu.2020.613815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Anger-Góra N, Węgierek-Ciura K, Szczygieł A, Mierzejewska J, Pajtasz-Piasecka E, Rossowska J. Treatment with lentiviral vectors encoding shRNA against interleukin 10 modulates the immunosuppressive activity of murine colon carcinoma-associated myeloid-derived suppressor cells. Oncol Lett 2021;22:582. [PMID: 34122633 DOI: 10.3892/ol.2021.12843] [Reference Citation Analysis]
61 Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M, Gagliani N, Meroni P, Abrignani S, Flavell RA. The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine & Growth Factor Reviews 2016;30:87-93. [DOI: 10.1016/j.cytogfr.2016.02.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 12.6] [Reference Citation Analysis]
62 Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer Control 2013;20:7-16. [PMID: 23302902 DOI: 10.1177/107327481302000103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
63 Seto T, Sam D, Pan M. Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Med Sci (Basel) 2019;7:E14. [PMID: 30678257 DOI: 10.3390/medsci7020014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
64 Yaseen MM, Abuharfeil NM, Darmani H, Daoud A. Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine. Open Biol 2020;10:200111. [PMID: 32931721 DOI: 10.1098/rsob.200111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
65 Chen P, Pan W, Wu C, Yeh C, Korupalli C, Luo P, Chou C, Chia W, Sung H. Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials 2020;230:119629. [DOI: 10.1016/j.biomaterials.2019.119629] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 37.0] [Reference Citation Analysis]
66 Kalinski P, Talmadge JE. Tumor Immuno-Environment in Cancer Progression and Therapy. Adv Exp Med Biol 2017;1036:1-18. [PMID: 29275461 DOI: 10.1007/978-3-319-67577-0_1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
67 Yang A, Bai Y, Dong X, Ma T, Zhu D, Mei L, Lv F. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy. Acta Biomater 2021;133:257-67. [PMID: 34407475 DOI: 10.1016/j.actbio.2021.08.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Batchu RB, Gruzdyn OV, Kolli BK, Dachepalli R, Umar PS, Rai SK, Singh N, Tavva PS, Weaver DW, Gruber SA. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer. Adv Exp Med Biol 2021;1290:51-65. [PMID: 33559854 DOI: 10.1007/978-3-030-55617-4_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Abbas M, Mason T, Ibad A, Khraiwesh M, Apprey V, Kanaan Y, Wilson B, Dunston G, Ricks-Santi L, Brim H. Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans. Anticancer Res 2020;40:27-34. [PMID: 31892550 DOI: 10.21873/anticanres.13923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Cai C, Zhang J, Li M, Wu Z, Song KH, Zhan TW, Wang L, Sun Y. Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma. Tumor Biol 2016;37:8209-18. [DOI: 10.1007/s13277-015-4687-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
71 Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, Hu H, Das M, Goodwin TJ, Liu R, Huang L. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. ACS Nano 2018;12:9830-41. [PMID: 30253648 DOI: 10.1021/acsnano.8b00967] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]
72 Ma L, Wang L, Nelson AT, Han C, He S, Henn MA, Menon K, Chen JJ, Baek AE, Vardanyan A, Shahoei SH, Park S, Shapiro DJ, Nanjappa SG, Nelson ER. 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression. Cancer Lett 2020;493:266-83. [PMID: 32861706 DOI: 10.1016/j.canlet.2020.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
73 Coluccio ML, Presta I, Greco M, Gervasi R, La Torre D, Renne M, Voci CP, Lunelli L, Donato G, Malara N. Microenvironment Molecular Profile Combining Glycation Adducts and Cytokines Patterns on Secretome of Short-term Blood-derived Cultures during Tumour Progression. Int J Mol Sci 2020;21:E4711. [PMID: 32630302 DOI: 10.3390/ijms21134711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
74 Chen S, Wang X, Wu X, Wei MQ, Zhang B, Liu X, Wang Y. IL-10 signalling blockade at the time of immunization inhibits Human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice. Cellular Immunology 2014;290:145-51. [DOI: 10.1016/j.cellimm.2014.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
75 Zhu S, Luo Z, Li X, Han X, Shi S, Zhang T. Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications. J Cancer 2021;12:54-64. [PMID: 33391402 DOI: 10.7150/jca.49692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
76 Hsu FT, Chen TC, Chuang HY, Chang YF, Hwang JJ. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. Oncotarget 2015;6:44134-50. [PMID: 26683520 DOI: 10.18632/oncotarget.6628] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
77 Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma 2013;54:2112-21. [PMID: 23432691 DOI: 10.3109/10428194.2013.778409] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
78 Chang CM, Lam HYP, Hsu HJ, Jiang SJ. Interleukin-10: A double-edged sword in breast cancer. Tzu Chi Med J 2021;33:203-11. [PMID: 34386356 DOI: 10.4103/tcmj.tcmj_162_20] [Reference Citation Analysis]
79 Moreno Ayala MA, Gottardo MF, Imsen M, Asad AS, Bal de Kier Joffé E, Casares N, Lasarte JJ, Seilicovich A, Candolfi M. Therapeutic blockade of Foxp3 in experimental breast cancer models. Breast Cancer Res Treat 2017;166:393-405. [PMID: 28756536 DOI: 10.1007/s10549-017-4414-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
80 Han M, Sun P, Li Y, Wu G, Nie J. Structural characterization of a polysaccharide from Sargassum henslowianum, and its immunomodulatory effect on gastric cancer rat. International Journal of Biological Macromolecules 2018;108:1120-7. [DOI: 10.1016/j.ijbiomac.2017.12.109] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
81 Pye RJ, Woods GM, Kreiss A. Devil Facial Tumor Disease. Vet Pathol 2016;53:726-36. [PMID: 26657222 DOI: 10.1177/0300985815616444] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
82 Gopal M. Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer. In: Rezaei N, editor. Cancer Immunology. Berlin: Springer Berlin Heidelberg; 2015. pp. 93-119. [DOI: 10.1007/978-3-662-44006-3_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
83 Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res 2014;74:3556-66. [PMID: 24769442 DOI: 10.1158/0008-5472.CAN-13-3225] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 4.9] [Reference Citation Analysis]
84 Campion CA, Soden D, Forde PF. Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models. BMC Cancer 2016;16:462. [PMID: 27412241 DOI: 10.1186/s12885-016-2536-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
85 Liu B, Wu C, He X, Zhuo R, Cheng S. Multi-drug loaded vitamin E-TPGS nanoparticles for synergistic drug delivery to overcome drug resistance in tumor treatment. Science Bulletin 2016;61:552-60. [DOI: 10.1007/s11434-016-1039-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
86 Rickmann M, Macke L, Sundarasetty BS, Stamer K, Figueiredo C, Blasczyk R, Heuser M, Krauter J, Ganser A, Stripecke R. Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Ann Hematol 2013;92:1079-90. [PMID: 23616009 DOI: 10.1007/s00277-013-1744-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
87 Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6:1359-1381. [PMID: 25682197 DOI: 10.18632/oncotarget.3204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
88 Doello K. The role of trophoblastic epigenetic reprogrammation in benign tumor cells on malignant progression: A molecular hypothesis. Med Hypotheses 2018;113:68-71. [PMID: 29523298 DOI: 10.1016/j.mehy.2018.02.019] [Reference Citation Analysis]
89 Hong E, Dobrovolskaia MA. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. Advanced Drug Delivery Reviews 2019;141:3-22. [DOI: 10.1016/j.addr.2018.01.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
90 Jiang L, Ding Y, Xue X, Zhou S, Li C, Zhang X, Jiang X. Entrapping multifunctional dendritic nanoparticles into a hydrogel for local therapeutic delivery and synergetic immunochemotherapy. Nano Res 2018;11:6062-73. [DOI: 10.1007/s12274-018-2123-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
91 Benvegnen J, De Breuyn B, Gerber V, Rottenberg S, Koch C. Immunohistochemical Analysis of Programmed Death-Ligand 1 Expression in Equine Sarcoids. J Equine Vet Sci 2021;97:103338. [PMID: 33478763 DOI: 10.1016/j.jevs.2020.103338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Bien E, Krawczyk M, Izycka-Swieszewska E, Trzonkowski P, Kazanowska B, Adamkiewicz-Drozynska E, Balcerska A. Deregulated systemic IL-10/IL-12 balance in advanced and poor prognosis paediatric soft tissue sarcomas. Biomarkers 2013;18:204-15. [PMID: 23557126 DOI: 10.3109/1354750X.2013.764351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
93 Bao D, Zhang C, Li L, Wang H, Li Q, Ni L, Lin Y, Huang R, Yang Z, Zhang Y, Hu Y. Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer. Front Oncol 2020;10:553297. [PMID: 33614473 DOI: 10.3389/fonc.2020.553297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Truffi M, Mazzucchelli S, Bonizzi A, Sorrentino L, Allevi R, Vanna R, Morasso C, Corsi F. Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy. Int J Mol Sci 2019;20:E1263. [PMID: 30871158 DOI: 10.3390/ijms20061263] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
95 Nikkhoo A, Rostami N, Farhadi S, Esmaily M, Moghadaszadeh Ardebili S, Atyabi F, Baghaei M, Haghnavaz N, Yousefi M, Aliparasti MR, Ghalamfarsa G, Mohammadi H, Sojoodi M, Jadidi-Niaragh F. Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression. Int J Pharm 2020;581:119236. [PMID: 32240809 DOI: 10.1016/j.ijpharm.2020.119236] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
96 Bommareddy PK, Silk AW, Kaufman HL. Intratumoral Approaches for the Treatment of Melanoma. The Cancer Journal 2017;23:40-7. [DOI: 10.1097/ppo.0000000000000234] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 7.8] [Reference Citation Analysis]
97 Li Y, Rong J, Qin J, He JY, Chen HG, Huang SH. Micro RNA-98 interferes with expression interleukin-10 in peripheral B cells of patients with lung cancer. Sci Rep 2016;6:32754. [PMID: 27605397 DOI: 10.1038/srep32754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
98 Keller XE, Kardas P, Acevedo C, Sais G, Poyet C, Banzola I, Mortezavi A, Seifert B, Sulser T, Hirsch HH, Provenzano M. Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. Oncotarget 2015;6:6459-69. [PMID: 25749042 DOI: 10.18632/oncotarget.3363] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
99 Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. 2015;4:e1016700. [PMID: 26140242 DOI: 10.1080/2162402x.2015.1016700] [Cited by in Crossref: 133] [Cited by in F6Publishing: 89] [Article Influence: 22.2] [Reference Citation Analysis]
100 Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017;28:437-448. [PMID: 27530312 DOI: 10.1089/hum.2016.025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
101 Etxebeste-Mitxeltorena M, Del Rincón-Loza I, Martín-Antonio B. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. Front Immunol 2021;12:717850. [PMID: 34447383 DOI: 10.3389/fimmu.2021.717850] [Reference Citation Analysis]
102 Kundu M, Roy A, Pahan K. Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-γ. Proc Natl Acad Sci U S A 2017;114:11482-7. [PMID: 29073075 DOI: 10.1073/pnas.1705536114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
103 Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ. Immunological effects of everolimus in patients with metastatic renal cell cancer. Int J Immunopathol Pharmacol 2017;30:341-52. [PMID: 28988508 DOI: 10.1177/0394632017734459] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
104 Le Buanec H, Bensussan A, Bagot M, Gallo RC, Zagury D. Active and passive anticytokine immune therapies: current status and development. Adv Immunol 2012;115:187-227. [PMID: 22608260 DOI: 10.1016/B978-0-12-394299-9.00007-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 2013;12:285-95. [PMID: 23496668 DOI: 10.1586/erv.13.22] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
106 Wu X, Hsu DK, Wang KH, Huang Y, Mendoza L, Zhou Y, Hwang ST. IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model. Leuk Lymphoma 2019;60:1244-52. [PMID: 30277131 DOI: 10.1080/10428194.2018.1516037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
107 Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Letters 2015;367:103-7. [DOI: 10.1016/j.canlet.2015.07.009] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 32.8] [Reference Citation Analysis]
108 Zhao S, Wu D, Wu P, Wang Z, Huang J. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis. PLoS One. 2015;10:e0139598. [PMID: 26440936 DOI: 10.1371/journal.pone.0139598] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 8.5] [Reference Citation Analysis]
109 Sill M, Schröder C, Shen Y, Marzoq A, Komel R, Hoheisel JD, Nienhüser H, Schmidt T, Kastelic D. Protein Profiling Gastric Cancer and Neighboring Control Tissues Using High-Content Antibody Microarrays. Microarrays (Basel) 2016;5:E19. [PMID: 27600085 DOI: 10.3390/microarrays5030019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
110 Kasamatsu T, Saitoh T, Minato Y, Shimizu H, Yokohama A, Tsukamoto N, Handa H, Sakura T, Murakami H. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome. Eur J Haematol 2016;96:245-51. [DOI: 10.1111/ejh.12577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Santos J, Brito M, Ferreira R, Moura AP, Sousa T, Batista T, Mangueira V, Leite F, Cruz R, Vieira G, Lira B, Athayde-Filho P, Souza H, Costa N, Veras R, Barbosa-Filho JM, Magalhães H, Sobral M. Th1-Biased Immunomodulation and In Vivo Antitumor Effect of a Novel Piperine Analogue. Int J Mol Sci 2018;19:E2594. [PMID: 30200386 DOI: 10.3390/ijms19092594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
112 Gueuvoghlanian-Silva BY, Bellelis P, Barbeiro DF, Hernandes C, Podgaec S. Treg and NK cells related cytokines are associated with deep rectosigmoid endometriosis and clinical symptoms related to the disease. J Reprod Immunol 2018;126:32-8. [PMID: 29477012 DOI: 10.1016/j.jri.2018.02.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
113 Rossowska J, Anger N, Szczygieł A, Mierzejewska J, Pajtasz-Piasecka E. Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy. J Exp Clin Cancer Res 2018;37:126. [PMID: 29954431 DOI: 10.1186/s13046-018-0799-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
114 Shen KY, Song YC, Chen IH, Chong P, Liu SJ. Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother 2014;10:3241-50. [PMID: 25483652 DOI: 10.4161/hv.29275] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
115 Heo G, Lee Y, Im E. Interplay between the Gut Microbiota and Inflammatory Mediators in the Development of Colorectal Cancer. Cancers (Basel) 2021;13:734. [PMID: 33578830 DOI: 10.3390/cancers13040734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 Wu C, Gong MQ, Liu BY, Zhuo RX, Cheng SX. Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance. Colloids Surf B Biointerfaces 2017;149:250-9. [PMID: 27768915 DOI: 10.1016/j.colsurfb.2016.10.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
117 Hu D, Wan L, Chen M, Caudle Y, LeSage G, Li Q, Yin D. Essential role of IL-10/STAT3 in chronic stress-induced immune suppression. Brain Behav Immun 2014;36:118-27. [PMID: 24513872 DOI: 10.1016/j.bbi.2013.10.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
118 Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4:173. [PMID: 27275486 DOI: 10.21037/atm.2016.03.34] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
119 Martel AL, Fraleigh NL, Picard E, Lewicky JD, Pawelec G, Lee H, Ma GW, Mousavifar L, Roy R, Le HT. Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposome. Int J Pharm 2021;606:120849. [PMID: 34216770 DOI: 10.1016/j.ijpharm.2021.120849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Ma H, Chen S, He Y, Huang J, Xu Y, Wang C, Lei C, Lu T, Xiao S, Mao J, Xu Y, Guo H, Li B, Zhang M, He X. Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment. Protein Cell 2018;9:664-9. [PMID: 29143211 DOI: 10.1007/s13238-017-0489-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Pandey VK, Amin PJ, Shankar BS. COX-2 inhibitor prevents tumor induced down regulation of classical DC lineage specific transcription factor Zbtb46 resulting in immunocompetent DC and decreased tumor burden. Immunol Lett 2017;184:23-33. [PMID: 28161224 DOI: 10.1016/j.imlet.2017.01.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
122 Zhu C, Lin S, Liang J, Zhu Y. PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma. Cryobiology 2019;87:86-90. [DOI: 10.1016/j.cryobiol.2019.01.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Xie M, Wei J, Xu J. Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer. Front Immunol 2020;11:676. [PMID: 32425930 DOI: 10.3389/fimmu.2020.00676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
124 Rivas JR, Liu Y, Alhakeem SS, Eckenrode JM, Marti F, Collard JP, Zhang Y, Shaaban KA, Muthusamy N, Hildebrandt GC, Fleischman RA, Chen L, Thorson JS, Leggas M, Bondada S. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia 2021. [PMID: 33731852 DOI: 10.1038/s41375-021-01217-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Perng P, Lim M. Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol 2015;5:153. [PMID: 26217588 DOI: 10.3389/fonc.2015.00153] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 13.5] [Reference Citation Analysis]
126 Abumaree MH, Al Harthy S, Al Subayyil AM, Alshabibi MA, Abomaray FM, Khatlani T, Kalionis B, El-Muzaini MF, Al Jumah MA, Jawdat D, Alawad AO, AlAskar AS. Decidua Basalis Mesenchymal Stem Cells Favor Inflammatory M1 Macrophage Differentiation In Vitro. Cells 2019;8:E173. [PMID: 30781712 DOI: 10.3390/cells8020173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
127 Atoum MF. ACC interleukin-10 gene promoter haplotype as a breast cancer risk factor predictor among Jordanian females. Onco Targets Ther 2016;9:3353-7. [PMID: 27330315 DOI: 10.2147/OTT.S101628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
128 Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS. T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. Front Immunol 2019;10:2453. [PMID: 31681327 DOI: 10.3389/fimmu.2019.02453] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 28.0] [Reference Citation Analysis]
129 Zhang Y, Zheng Y, Shou L, Shi Y, Shen H, Zhu M, Ye X, Jin J, Xie W. Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas. Front Oncol 2020;10:584261. [PMID: 33154947 DOI: 10.3389/fonc.2020.584261] [Reference Citation Analysis]
130 Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers (Basel) 2021;13:5189. [PMID: 34680337 DOI: 10.3390/cancers13205189] [Reference Citation Analysis]
131 Yang C, Zhang DM, Song ZB, Hou YQ, Bao YL, Sun LG, Yu CL, Li YX. Protumoral TSP50 Regulates Macrophage Activities and Polarization via Production of TNF-α and IL-1β, and Activation of the NF-κB Signaling Pathway. PLoS One 2015;10:e0145095. [PMID: 26684869 DOI: 10.1371/journal.pone.0145095] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
132 Goldman N, Lomakova YD, Londregan J, Bucknum A, DePierri K, Somerville J, Riggs JE. High macrophage PD-L1 expression not responsible for T cell suppression. Cell Immunol 2018;324:50-8. [PMID: 29305065 DOI: 10.1016/j.cellimm.2017.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
133 Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z, Liu L. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res 2018;46:5228-36. [PMID: 30304975 DOI: 10.1177/0300060518800588] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
134 Schouppe E, De Baetselier P, Van Ginderachter JA, Sarukhan A. Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology 2012;1:1135-45. [PMID: 23170260 DOI: 10.4161/onci.21566] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
135 Rehm A, Gätjen M, Gerlach K, Scholz F, Mensen A, Gloger M, Heinig K, Lamprecht B, Mathas S, Bégay V, Leutz A, Lipp M, Dörken B, Höpken UE. Dendritic cell-mediated survival signals in Eμ-Myc B-cell lymphoma depend on the transcription factor C/EBPβ. Nat Commun 2014;5:5057. [PMID: 25266931 DOI: 10.1038/ncomms6057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
136 de Vries CR, Kaufman HL, Lattime EC. Oncolytic viruses: focusing on the tumor microenvironment. Cancer Gene Ther 2015;22:169-71. [PMID: 25721204 DOI: 10.1038/cgt.2015.11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
137 Vuillefroy de Silly R, Ducimetière L, Yacoub Maroun C, Dietrich PY, Derouazi M, Walker PR. Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells. Eur J Immunol 2015;45:2263-75. [PMID: 25929785 DOI: 10.1002/eji.201445284] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
138 D'souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M. MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. Adv Biochem Eng Biotechnol 2013;130:209-66. [PMID: 22990585 DOI: 10.1007/10_2012_150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
139 Jiang C, Yuan F, Wang J, Wu L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology 2017;222:651-7. [PMID: 28017495 DOI: 10.1016/j.imbio.2016.12.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
140 Pucelik B, Arnaut LG, Dąbrowski JM. Lipophilicity of Bacteriochlorin-Based Photosensitizers as a Determinant for PDT Optimization through the Modulation of the Inflammatory Mediators. J Clin Med 2019;9:E8. [PMID: 31861531 DOI: 10.3390/jcm9010008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
141 Sakakura K, Chikamatsu K. Immune suppression and evasion in patients with head and neck cancer. Advances in Cellular and Molecular Otolaryngology 2013;1:21809. [DOI: 10.3402/acmo.v1i0.21809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]